

EA CONGRESS
DV 2026

VIENNA
30 SEP - 3 OCT

TOGETHER FOR BETTER

**INDUSTRY SESSIONS
PROGRAMME**

A photograph of St. Stephen's Cathedral in Vienna, Austria, featuring its iconic green-tiled roof and the tall, ornate spire of St. Stephen's. The image is partially obscured by a large, semi-transparent white graphic element that frames the text.

Industry session organisers

Platinum sponsors



Gold sponsors



Silver sponsors



Bronze sponsors



EADV Supporters



Medical education agencies



Table of contents

Industry sessions..... 5

Satellite Symposia..... 6

 Wednesday, 30 September 2026..... 6

 Thursday, 1 October 202618

 Friday, 2 October 202638

Industry Expert Hubs53

 Wednesday, 30 September 2026.....53

 Thursday, 1 October 202662

 Friday, 2 October 202676



Industry sessions

The EADV Industry Partners organise several sessions as an adjunct to the EADV Scientific Sessions. The sessions are organised by the companies and feature presentations by experts in the field, panel discussions and other type of sessions.

The industry sessions are a valuable way to learn about new research, techniques or treatments in the field of dermatology and venereology. In addition, some sessions will focus on sharing information about new products, services and/or technologies available.

At the EADV Congress, two different types of industry sessions are organised:

Satellite symposia

Satellite symposia are organised in the main session rooms and take place in the morning, during lunch breaks and after the last session of the day. These sessions last between 45, 60 and 90 minutes and offer a wider education on the presented topic to remain updated on any progression in the field

Industry expert hubs

Industry expert hubs are organised on the Level - 2 of the Austria Center Vienna. These sessions last 45 minutes and are focused on bringing together a smaller group of experts to discuss more in-depth or to focus on a specific topic

Industry sessions programme

The industry session organiser is solely responsible for keeping any of its industry sessions activities compliant with all relevant laws and regulations. EADV is not involved with or have any control over the content, quality, organisation, operation, scientific integrity of the activity and materials. EADV will not be involved in the selection of speakers, moderators and other faculty.

Access to industry sessions

As a multidisciplinary audience will be attending the EADV Congress 2026, please make sure to select the right category, Healthcare Professionals (HCPs) and Non-Healthcare Professionals (NON-HCPs), during the registration process. Access to any industry sessions where data or research of prescription medicines is presented will be limited exclusively to Healthcare Professionals (HCPs) and Non Members (INDUSTRY).

Industry session organisers may limit participation to certain representative groups independently from EADV recommendations if deemed imperative to the achievement of the intended purpose of the Industry session.

Please note that exhibitor tickets allow access only to industry sessions organised by the same company. Access to industry sessions of other companies is not allowed.



Satellite Symposia

Wednesday, 30 September 2026

	Lunch symposia 13:00 - 14:00	
Hall D		
Hall B	<u>SAT 2.01</u>	Pfizer Non-segmental vitiligo: Pathogenesis, Assessment, and Treatment Considerations
Hall C	<u>SAT 3.01</u>	Johnson & Johnson Psoriasis
Hall F1	<u>SAT 4.01</u>	Regeneron Cutaneous Squamous Cell Carcinoma
Hall F2	<u>SAT 5.01</u>	Eli Lilly and Company New Frontiers in Alopecia Areata: Newly Released Baricitinib Adolescent Data, Real-World Evidence, and Clinical Perspectives
Hall E1	SAT 6.01	Glenmark Pharmaceuticals Acne Vulgaris, Androgen pathway, clinical management
Hall E2	SAT 7.01	PeerVoice Cutaneous lupus erythematosus (CLE)
Hall G	<u>SAT 8.01</u>	Sanofi / Regeneron Atopic Dermatitis
Hall K		
Hall M	<u>SAT 10.01</u>	Novartis Pharma AG Hidradenitis suppurativa
Hall N	<u>SAT 11.01</u>	Biogen Cutaneous Lupus Erythematosus

	Access restricted to healthcare professionals (HCPs) and INDUSTRY badges.	Access restricted to Healthcare Professionals (HCPs) only. No access to INDUSTRY badges.	Session open to all
--	---	--	---------------------



Satellite Symposia

Wednesday, 30 September 2026

SAT 2.01

Room: Hall B

Access: HCP and Non Member (INDUSTRY)

Time: 13:00 – 14:00 CEST



SAT 2.01		Non-segmental vitiligo: Pathogenesis, Assessment, and Treatment Considerations
SAT 2.01.01	13:00	Welcome and Introductions Khaled Ezzedine (Créteil, France)
SAT 2.01.02	13:05	An overview of the multifactorial pathophysiology of vitiligo Thierry Passeron (Nice, France)
SAT 2.01.03	13:25	Clinical tips for assessing a patient with vitiligo Khaled Ezzedine (Créteil, France) Thierry Passeron (Nice, France)
SAT 2.01.04	13:45	Identifying suitable patients for systemic therapies Khaled Ezzedine (Créteil, France) Thierry Passeron (Nice, France)
SAT 2.01.05	13:55	Discussion Khaled Ezzedine (Créteil, France) Thierry Passeron (Nice, France)

Satellite Symposia

Wednesday, 30 September 2026

SAT 3.01

Room: Hall C

Access: HCPs only*

Time: 13:00 – 14:00 CEST

Johnson & Johnson

Johnson & Johnson

SAT 3.01		Orchestrating innovation in psoriasis care Chairs: Diamant Thaçi (Lübeck, Germany) Richard Warren (Manchester, United Kingdom)
SAT 3.01.01	13:00	Prelude Diamant Thaçi (Lübeck, Germany)
SAT 3.01.02	13:03	First movement: changing the rhythm in psoriasis care Álvaro González-Cantero (Madrid, Spain)
SAT 3.01.03	13:18	IL-23: the conductor of inflammation in psoriasis Álvaro González-Cantero (Madrid, Spain)
SAT 3.01.04	13:21	Second movement: changing the tempo with early intervention Andreas Pinter (Frankfurt, Germany)
SAT 3.01.05	13:36	Third movement: a new melody in the IL-23 repertoire Richard Warren (Manchester, United Kingdom)
SAT 3.01.06	13:51	Panel discussion: bringing the score to practice Diamant Thaçi (Lübeck, Germany) Richard Warren (Manchester, United Kingdom) Álvaro González-Cantero (Madrid, Spain) Andreas Pinter (Frankfurt, Germany)
SAT 3.01.07	13:57	Final notes: closing remarks Diamant Thaçi (Lübeck, Germany)

* No access to INDUSTRY badges



Satellite Symposia

Wednesday, 30 September 2026

SAT 4.01

Room: Hall F1

Access: HCP and Non Member (INDUSTRY)

Time: 13:00 – 14:00 CEST

REGENERON®

Regeneron

SAT 4.01		Collaborative Care Approaches for Cutaneous Squamous Cell Carcinoma (CSCC) Chair: Christoph Hoeller (Vienna, Austria)
SAT 4.01.01	13:00	Welcome and Introductions Christoph Hoeller (Vienna, Austria)
SAT 4.01.02	13:05	Identifying Patients with High-Risk Features in CSCC: A Dermatologist's Perspective Marlies Wakkee (Rotterdam, Netherlands)
SAT 4.01.03	13:15	Innovations in Adjuvant Therapy for High-Risk CSCC Dirk Schadendorf (Essen, Germany)
SAT 4.01.04	13:35	Clinical Decision-Making and Treatment Strategies for Advanced CSCC Christoph Hoeller (Vienna, Austria)
SAT 4.01.05	13:50	Q&A Dirk Schadendorf (Essen, Germany) Christoph Hoeller (Vienna, Austria) Marlies Wakkee (Rotterdam, Netherlands)

Satellite Symposia

Wednesday, 30 September 2026

SAT 5.01

Room: Hall F2

Access: HCP and Non Member (INDUSTRY)

Time: 13:00 – 14:00 CEST



Eli Lilly and Company

SAT 5.01		New Frontiers in Alopecia Areata: Newly Released Baricitinib Adolescent Data, Real-World Evidence, and Clinical Perspectives Chair: Brett King (Fairefield, United States)
SAT 5.01.01	13:00	Welcome, Disclosures, and Programme Overview Brett King (Fairefield, United States)
SAT 5.01.02	13:05	Putting It into Practice: An Adolescent AA Patient Case Sergio Vano Galvan (Madrid, Spain)
SAT 5.01.03	13:20	Newly Released Data: Baricitinib in Adolescent Alopecia Areata Brett King (Fairefield, United States)
SAT 5.01.04	13:35	Beyond the Trial: Real-World Evidence for Baricitinib in Adolescent AA Michela Starace (Bologna, Italy)
SAT 5.01.05	13:50	Interactive Q&A and Expert Panel Discussion Brett King (Fairefield, United States)
SAT 5.01.06	13:58	Closing Remarks and Key Takeaways Brett King (Fairefield, United States)

Satellite Symposia

Wednesday, 30 September 2026

SAT 6.01

Room: Hall E1

Access: HCP and Non Member (INDUSTRY)

Time: 13:00 – 14:00 CEST



Glenmark Pharmaceuticals

SAT 6.01		Clinical Management of Androgen Mediated Sebum Pathway in Acne Vulgaris: How has it changed? Chair: Alison Layton (Harrogate, United Kingdom)
SAT 6.01.01	13:00	From sebum to inflammation: Why targeting the sebaceous gland may hold the key to Acne management? Brigitte Dréno (Nantes, France)
SAT 6.01.02	13:15	What's the clinical evidence for topical anti-androgens and sebum modifying agents in the current acne landscape? Alison Layton (Harrogate, United Kingdom)
SAT 6.01.03	13:30	Time to rethink Acne Vulgaris management - Case studies Hilary Baldwin (Brooklyn, United States)
SAT 6.01.04	13:45	Q&A Alison Layton (Harrogate, United Kingdom) Brigitte Dréno (Nantes, France) Hilary Baldwin (Brooklyn, United States)

Clinical Management of Androgen Mediated Sebum Pathway in Acne Vulgaris: How has it changed?

SAVE THE DATE!

📍 HALL E1 - SAT 6.01 📅 WED, 30 SEP 2026 🕒 01:00 PM - 02:00 PM

Don't miss the symposium dedicated to the pathogenesis and management of Acne Vulgaris! Join us for an interactive session to discuss how the evolving therapeutic landscape may address unmet clinical needs.

From sebum to inflammation: Why targeting the sebaceous gland may hold the key to Acne management?


Brigitte Dréno (Nantes, France)

What's the clinical evidence for topical anti-androgens and sebum modifying agents in the current acne landscape?

Alison Layton (Harrogate, United Kingdom)

Time to rethink Acne Vulgaris management - Case studies

Hilary Baldwin (Brooklyn, United States)




glenmark
A new way for a new world

Come and discover the latest innovation in acne at our booth **X548***

*Access to the exhibition area is restricted to Healthcare Professionals only.

For Healthcare Professionals only. This session is organised and funded by Glenmark; Glenmark products may be discussed. Adverse events should be reported. In the UK, reporting forms and information can be found at www.mhra.gov.uk/yellowcard. In the EU, healthcare professionals are asked to report any suspected adverse reactions via their national reporting system. Adverse events should also be reported to medical_information@glenmarkpharma.com or by calling +44 (0)800 458 0383.

Satellite Symposia

Wednesday, 30 September 2026

SAT 7.01

Room: Hall E2

Access: HCP and Non Member (INDUSTRY)

Time: 13:00 – 14:00 CEST

PeerVoice

PeerVoice

Supported by an unrestricted educational grant from AstraZeneca

SAT 7.01		CLE Patient to Pathway: Integrating Patient Burden, Disease Heterogeneity, and the Evolving Therapeutic Landscape Chair: Michelle Min (Irvine, United States)
SAT 7.01.01	13:00	Welcome and Introduction Michelle Min (Irvine, United States)
SAT 7.01.02	13:05	CLE More Than the Skin: Understanding the Multidimensional Burden of CLE Michelle Min (Irvine, United States)
SAT 7.01.03	13:20	Not One Disease: How Pathophysiology Drives Heterogeneity in CLE Miriam Wittmann (Mainz, Germany)
SAT 7.01.04	13:35	Evolving Therapeutic Strategies in CLE: Clinical and Real World Insights Across the Interferon Pathway Ignasi Figueras-Nart (Barcelona, Spain)
SAT 7.01.05	13:50	Panel Discussion, Summary and Close Michelle Min (Irvine, United States) Miriam Wittmann (Mainz, Germany) Ignasi Figueras-Nart (Barcelona, Spain)

Satellite Symposia

Wednesday, 30 September 2026

SAT 8.01

Room: Hall G

Access: HCPs only and Non Member (INDUSTRY)

Time: 13:00 – 14:00 CEST

sanofi | REGENERON®

Sanofi / Regeneron

SAT 8.01		Atopic Dermatitis at an Inflection Point: Refining Outcomes Through Timely, Targeted Intervention Chair: Tilo Biedermann (Munich, Germany)
SAT 8.01.01	13:00	Welcome and Introductions Tilo Biedermann (Munich, Germany)
SAT 8.01.02	13:05	The Potential Sequelae of Missed Opportunities: How Systemic Type 2 Inflammation Can Shape a Patient's Life Nicole Chase (St. Paul, United States)
SAT 8.01.03	13:20	Breaking the Cycle of AD in Adults: Minimizing Cumulative Burden Beyond Skin and Achieving Sustained Disease Control Tilo Biedermann (Munich, Germany)
SAT 8.01.04	13:35	Early Intervention in Pediatric AD: A Critical Window to Alter the Course of AD and Associated Diseases Lisa Swanson (Boise, United States)
SAT 8.01.05	13:50	Audience Q&A Tilo Biedermann (Munich, Germany) Nicole Chase (St. Paul, United States) Lisa Swanson (Boise, United States)

Satellite Symposia

Wednesday, 30 September 2026

SAT 10.01

Room: Hall M

Access: HCPs only *

Time: 13:00 – 14:00 CEST

 **NOVARTIS**

Novartis Pharma AG

SAT 10.01		Setting the tempo in hidradenitis suppurativa (HS): From early recognition to individualized care Chair: Falk Bechara (Bochum, Germany)
SAT 10.01.01	13:00	Welcome and introduction Falk Bechara (Bochum, Germany)
SAT 10.01.02	13:05	Establishing the tone: Early recognition and timely intervention in HS Brian Kirby (Dublin, Ireland)
SAT 10.01.03	13:20	Layering in the harmonies: Understanding the multidimensional burden of HS Axel Villani (Lyon, France)
SAT 10.01.04	13:35	Fine-tuning the composition: Practical approaches to individualized treatment in HS Falk Bechara (Bochum, Germany)
SAT 10.01.05	13:50	Summary and audience Q&A Falk Bechara (Bochum, Germany) Axel Villani (Lyon, France) Brian Kirby (Dublin, Ireland)

* No access to INDUSTRY badges



You're invited to:

PRESS PLAY ON PROGRESS

A NEW ERA IN CSU MANAGEMENT

This interactive symposium will showcase emerging advances in CSU care, including firsthand clinical experience with remibrutinib, evidence-based guidance on when to escalate treatment, and actionable approaches for incorporating remibrutinib into routine clinical practice.

Key sessions

Behind the Scenes

Rethinking Unmet Needs
as CSU Practice Evolves

Press Play on Progress in CSU

Setting Expectations for
Fast Symptom Relief in
Many Patients

Director's Cut

Real-World Experience
and Impact of Remibrutinib
in Practice



Thursday, 1 October 2026

13:00-14:00 CET



SAT 5.03 - Hall F2

Chair



Prof. Dr. med. Martin Metz
Germany

Panel



Prof. Simon Francis Thomsen
Denmark



Dr. Dawn Merritt
United States

Additional faculty may join the panel.

This symposium is organized and funded by Novartis and is intended for an audience of non-UK HCPs within the context of the EADV Congress 2026 in Vienna, Austria.

©2026 Novartis Pharma AG | CH-4002 Basel, Switzerland | www.novartis.com

 **NOVARTIS**

FA-11707734 June 2026

Satellite Symposia

Wednesday, 30 September 2026

SAT 11.01

Room: Hall N

Access: HCP and Non Member (INDUSTRY)

Time: 13:00 – 14:00 CEST



SAT 11.01		Setting Cutaneous Lupus Erythematosus: Seeing the Full Picture - From Presentation to Unmet Need Chair: Joseph F. Merola (Dallas, United States) Francois Chasset (Paris, France)
SAT 11.01.01	13:00	Welcome and Introductions Joseph F. Merola (Dallas, United States)
SAT 11.01.02	13:05	Cutaneous Lupus Erythematosus: Clinical Spectrum and Pathobiology Joseph F. Merola (Dallas, United States)
SAT 11.01.03	13:20	Beyond Symptoms: Disease Burden and Real-World Management of CLE Francois Chasset (Paris, France)
SAT 11.01.04	13:35	Where We Fall Short and Where We're Going: Unmet Needs and Emerging Therapies in CLE Francois Chasset (Paris, France) Joseph F. Merola (Dallas, United States)
SAT 11.01.05	13:50	Q&A Joseph F. Merola (Dallas, United States) Francois Chasset (Paris, France)

Satellite Symposia

Thursday, 1 October 2026

		Lunch symposia 13:00 - 14:00		Evening symposia 17:45 - 19:15
Hall D	SAT 1.03	Eucerin Acne / Acne-prone skin / Skin microbiome / C. acnes dysbiosis / Skin-native probiotics		
Hall B	SAT 2.03	Pfizer Atopic Dermatitis and Alopecia Areata		
Hall C	SAT 3.03	UCB Psoriasis / Hidradenitis suppurativa (HS)		
Hall F1	SAT 4.03	Eli Lilly and Company Psoriasis, Psoriasis and comorbidities, Psoriasis and obesity		
Hall F2	SAT 5.03	Novartis Pharma AG Remibrutinib in CSU: Clinical evidence and experience	SAT 5.04	Medscape Education Global GLP-1 treatment and aesthetic facial changes
Hall E1	SAT 6.03	AbbVie Selective IL 23 inhibition for head to toe psoriasis control	SAT 6.04	Cheplapharm Confident use of isotretinoin for severe acne
Hall E2	SAT 7.03	La Roche Posay Pigmentation correction		
Hall G	SAT 8.03	Sanofi and Regeneron Type 2 inflammation		
Hall K	SAT 9.03	Incyte Emerging therapies for moderate-to- severe hidradenitis suppurativa		
Hall M	SAT 10.03	AVENE Atopic dermatitis	SAT 10.04	Novartis Pharma AG Psoriasis
Hall N	SAT 11.03	Johnson & Johnson Psoriasis	SAT 11.04	Almirall Redefining Psoriasis Success Beyond PASI

Access restricted to healthcare
professionals (HCPs) and
INDUSTRY badges.

Access restricted to Healthcare
Professionals (HCPs) only.
No access to INDUSTRY badges.

Session open to all

Satellite Symposia

Thursday, 1 October 2026

SAT 1.03

Room: Hall D

Access: Session open to all

Time: 13:00 – 14:00 CEST



Eucerin

SAT 1.03		Breaking the rules What if acne-prone skin care started working with bacteria - not against them? Chair: Marco Rocha (Sao Paulo, Brazil)
SAT 1.03.01	13:00	C. acnes: Understanding Strain Diversity in Acne-Prone Skin – The Evolving Role of the Skin Microbiome in Acne Care Alison Layton (Harrogate, United Kingdom)
SAT 1.03.02	13:10	Rebuilding a Health-Associated Microbiome – The Identification of Health-Associated, Skin-Native C. acnes Strains for Acne-Prone Skin Bernhard Paetzold (Ghent, Belgium)
SAT 1.03.03	13:25	Introducing the First Skin-Native Probiotic Routine – A New Era of Microbiome Modulation in Acne-Prone Skin Anne-Christin Worthmann (Hamburg, Germany)
SAT 1.03.04	13:40	Do Skin-Native Probiotics Deliver Clinical Benefit? Clinical Evidence in Monotherapy and Adjunctive Care for Acne-Prone Skin Marco Rocha (Sao Paulo, Brazil)



SCIENTIFIC SYMPOSIUM

BREAKING THE RULES

WHAT IF
ACNE-PRONE SKIN CARE
STARTED WORKING
WITH BACTERIA
— **NOT AGAINST THEM?**



DR MARCO ROCHA
BRAZIL



PROF ALISON LAYTON
UK



DR BERNHARD PAETZOLD
BELGIUM



ANNE-CHRISTIN WORTHMANN
GERMANY

01 THURSDAY
OCT
2026

13:00 – 14:00
ROOM: HALL D
LUNCHBOX PROVIDED

Satellite Symposia

Thursday, 1 October 2026

SAT 2.03

Room: Hall B

Access: HCP and Non Member (INDUSTRY)

Time: 13:00 – 14:00 CEST



SAT 2.03		Orchestrating Advanced Systemics in the Treatment of Moderate-to-Severe Atopic Dermatitis or Severe Alopecia Areata Chair: Seemal Desai (Dallas, United States) Brett King (Fairfield, United States)
SAT 2.03.01	13:00	Overture: Why M2S AD and Severe AA Demand Highly Conducted Treatment Choices Seemal Desai (Dallas, United States)
SAT 2.03.02	13:10	Mastering the Score: Translating AD Data Into Tailored Patient Care Seemal Desai (Dallas, United States)
SAT 2.03.03	13:30	Harmonising Data and Daily Life: Case Study in Severe Alopecia Areata Brett King (Fairfield, United States)
SAT 2.03.04	13:50	Summary and Audience Questions Brett King (Fairfield, United States) Seemal Desai (Dallas, United States)

Satellite Symposia

Thursday, 1 October 2026

SAT 3.03

Room: Hall C

Access: HCP and Non Member (INDUSTRY)

Time: 13:00 – 14:00 CEST



UCB

SAT 3.03		Bimekizumab spotlight sessions: Inflammation, early intervention & real-world impact
SAT 3.03.01	13:00	Welcome and introductions Amy Perkins (Glasgow, United Kingdom)
SAT 3.03.02	13:03	Inflammation spotlight: IL-17A and IL-17F pathways & clinical response in psoriasis and HS Angelo Marzano (Milan, Italy) Laura Savage (Leeds, United Kingdom) Eva Vilarrasa (Barcelona, Spain) Alexander Zink (Munich, Germany)
SAT 3.03.03	13:18	Early intervention spotlight: Clinical perspectives & disease trajectories Angelo Marzano (Milan, Italy) Laura Savage (Leeds, United Kingdom)
SAT 3.03.04	13:33	Real-world evidence spotlight: Translating insights into everyday care Eva Vilarrasa (Barcelona, Spain) Alexander Zink (Munich, Germany)
SAT 3.03.05	13:48	Audience Q&A Angelo Marzano (Milan, Italy) Laura Savage (Leeds, United Kingdom) Eva Vilarrasa (Barcelona, Spain) Alexander Zink (Munich, Germany)
SAT 3.03.06	13:58	Meeting close Amy Perkins (Glasgow, United Kingdom)



UCB welcomes you to EADV 2026



Satellite Symposia

Thursday, 1 October 2026

SAT 4.03

Room: Hall F1

Access: HCP and Non Member (INDUSTRY)

Time: 13:00 – 14:00 CEST



Eli Lilly and Company

SAT 4.03		Transforming Psoriasis Care: Why Dermatologists Need to Address Weight Management in Patients With Psoriasis and Overweight/Obesity Chair: Gudrun Ratzinger (Innsbruck, Austria)
SAT 4.03.01	13:00	The Unmet Medical Need: Disease Control in Psoriasis and the Impact of Overweight and Obesity Gudrun Ratzinger (Innsbruck, Austria)
SAT 4.03.02	13:10	The Intrinsic Connection Between Psoriatic Disease and Obesity Paolo Gisondi (Verona, Italy)
SAT 4.03.03	13:30	The Impact of Weight Reduction on Psoriasis: Results From the TOGETHER-PsO Trial and Their Clinical Considerations Mark Lebwohl (New York, United States)
SAT 4.03.04	13:50	Interactive Expert Exchange Gudrun Ratzinger (Innsbruck, Austria) Paolo Gisondi (Verona, Italy) Mark Lebwohl (New York, United States)



Satellite Symposia

Thursday, 1 October 2026

SAT 5.03

Room: Hall F2

Access: HCP only*

Time: 13:00 – 14:00 CEST

 NOVARTIS

Novartis Pharma AG

SAT 5.03		Press Play on Progress: A New Era in CSU Management Chair: Martin Metz (Berlin, Germany)
SAT 5.03.01	13:00	Welcome and Introduction Martin Metz (Berlin, Germany)
SAT 5.03.02	13:02	Behind the Scenes: Rethinking Unmet Needs as CSU Practice Evolves Martin Metz (Berlin, Germany)
SAT 5.03.03	13:12	Press Play on Progress in CSU: Setting Expectations for Fast Symptom Relief in Many Patients Simon Francis Thomsen (Copenhagen, Denmark)
SAT 5.03.04	13:25	Director's Cut: Real-World Experience and Impact of Remibrutinib in Practice Dawn Merritt (Columbus, United States) Fatima Albreiki (Al Ain, United Arab Emirates) Martin Metz (Berlin, Germany) Simon Francis Thomsen (Copenhagen, Denmark)
SAT 5.03.05	13:50	Q&A and Meeting Close Martin Metz (Berlin, Germany) Simon Francis Thomsen (Copenhagen, Denmark) Dawn Merritt (Columbus, United States) Fatima Albreiki (Al Ain, United Arab Emirates)

* No access to INDUSTRY badges

This symposium is organized and funded by Novartis and is intended for an audience of non-UK HCPs within the context of the EADV Congress 2026 in Vienna, Austria.

FA-11694814 June 2026



Satellite Symposia

Thursday, 1 October 2026

SAT 6.03

Room: Hall E1

Access: HCP and Non Member (INDUSTRY)

Time: 13:00 – 14:00 CEST

abbvie

AbbVie

SAT 6.03		Redefining the dermatology horizon: High control from head to toe with selective IL-23 cytokine inhibition in psoriasis Chair: Brian Kirby (Dublin, Ireland)
SAT 6.03.01	13:00	Setting the horizon Brian Kirby (Dublin, Ireland)
SAT 6.03.02	13:05	Looking ahead in psoriatic disease: Key biological drivers and the rationale for early IL-23 cytokine inhibition Brian Kirby (Dublin, Ireland)
SAT 6.03.03	13:20	Advancing head-to-toe psoriatic disease management April Armstrong (Los Angeles, United States)
SAT 6.03.04	13:35	Extending early and durable disease control beyond skin outcomes: Implications for PsA risk Matthias Augustin (Hamburg, Germany)
SAT 6.03.05	13:50	Bringing the horizons together: Panel discussion Brian Kirby (Dublin, Ireland) April Armstrong (Los Angeles, United States) Matthias Augustin (Hamburg, Germany)
SAT 6.03.06	13:55	Key takeaways Brian Kirby (Dublin, Ireland)

Satellite Symposia

Thursday, 1 October 2026

SAT 7.03

Room: Hall E2

Access: HCP and Non Member (INDUSTRY)

Time: 13:00 – 14:00 CEST

LA ROCHE POSAY
LABORATOIRE DERMATOLOGIQUE

La Roche Posay

SAT 7.03		Unmasking Pigmentation: A Dermatologist's Roadmap. From Prevention to Visible Correction Chair: Mukta Sachdev (Bengaluru, India)
SAT 7.03.01	13:00	Unmasking Pigmentation: Introduction Mukta Sachdev (Bengaluru, India)
SAT 7.03.02	13:05	Decoding Pigmentation: From Pathways to Practice-Changing Guidelines Rashmi Sarkar (New Delhi, India)
SAT 7.03.03	13:20	HEVL: the visible threat - how to broaden sunscreen protection Sergio Schalka (Cotia, Brazil)
SAT 7.03.04	13:35	Personalizing Pigmentation Correction: A Step-Up Approach That Delivers Visible Results Andrea Rey (Buenos Aires, Argentina)
SAT 7.03.05	13:50	Q&A Mukta Sachdev (Bengaluru, India)

Satellite Symposia

Thursday, 1 October 2026

SAT 8.03

Room: Hall G

Access: HCP and Non Member (INDUSTRY)

Time: 13:00 – 14:00 CEST

sanofi | REGENERON®

Sanofi and Regeneron

SAT 8.03		Same Fire, Different Smoke: Connecting Chronic Diseases Across Organs Through Type 2 Inflammation Chair: Raj Chovatiya (Chicago, United States)
SAT 8.03.01	13:00	Same Fire, Different Smoke: Why Type 2 Inflammation Is Getting More Attention Raj Chovatiya (Chicago, United States)
SAT 8.03.02	13:05	One Pathway, Many Faces Oscar Palomares (Madrid, Spain)
SAT 8.03.03	13:20	The Type 2 Playbook: Reframing AD, PN, and CSU Raj Chovatiya (Chicago, United States)
SAT 8.03.04	13:28	Targeting the Fire, Not the Smoke: Translating Mechanism into Clinical Impact Diamant Thaçi (Lübeck, Germany) Adam Friedman (Washington D.C., United States)
SAT 8.03.05	13:48	Join the Conversation: Audience Q&A Raj Chovatiya (Chicago, United States) Oscar Palomares (Madrid, Spain) Diamant Thaçi (Lübeck, Germany) Adam Friedman (Washington D.C., United States)
SAT 8.03.06	13:58	Closing remarks Raj Chovatiya (Chicago, United States)

Satellite Symposia

Thursday, 1 October 2026

SAT 9.03

Room: Hall K

Access: HCPs only *

Time: 13:00 – 14:00 CEST



Incyte

SAT 9.03		Reimagining hidradenitis suppurativa: From burden to breakthroughs Chair: John Ingram (Cardiff, United Kingdom)
SAT 9.03.01	13:00	Insights into understanding the full patient burden through the HERALD study John Ingram (Cardiff, United Kingdom)
SAT 9.03.02	13:20	Medical therapy, surgery or both? Falk Bechara (Bochum, Germany)
SAT 9.03.03	13:30	Advances in HS therapy Antonio Martorell (Valencia, Spain)
SAT 9.03.04	13:50	Q&A discussion John Ingram (Cardiff, United Kingdom) Falk Bechara (Bochum, Germany) Antonio Martorell (Valencia, Spain)

* No access to INDUSTRY badges



EADV 2026

THURSDAY, 1 OCTOBER 2026

13:00–14:00 CEST

HALL K, AUSTRIA CENTER

VIENNA, AUSTRIA

This session is restricted to
Healthcare Professionals only

REIMAGINING HIDRADENITIS SUPPURATIVA: FROM BURDEN TO BREAKTHROUGHS

EXPERT SYMPOSIUM

SESSIONS

- Chair and Q&A moderator | **Prof. John Ingram (UK)**
- Insights into understanding the full patient burden through the HERALD study | **Prof. John Ingram (UK)**
- Medical therapy, surgery or both? | **Prof. Falk Bechara (Germany)**
- Advances in HS therapy | **Dr Antonio Martorell (Spain)**
- Discussion | **All**

Satellite Symposia

Thursday, 1 October 2026

SAT 10.03

Room: Hall M

Access: Session open to all

Time: 13:00 – 14:00 CEST

EAU THERMALE
Avène
LABORATOIRE DERMATOLOGIQUE

AVENE

SAT 10.03		Can Atopic Dermatitis still surprise you in 2026? Chair: Peter Lio (Chicago, United States)
SAT 10.03.01	13:00	The expanding role of dermoscopy in atopic dermatitis Joanna Goldberg (Poznan, Poland)
SAT 10.03.02	13:10	Education as therapy: innovating childhood AD care Mauricio Torres-Pradilla (Bogota, Colombia)
SAT 10.03.03	13:20	From emollients to photoprotection: a comprehensive approach to the patient journey Peter Lio (Chicago, United States)
SAT 10.03.04	13:30	Is there a place for emollients in biotherapies ERA? Pedro Mendes Bastos (Lisbon, Portugal)



Satellite Symposia

Thursday, 1 October 2026

SAT 11.03

Room: Hall N

Access: HCPs only *

Time: 13:00 – 14:00 CEST

Johnson&Johnson

Johnson & Johnson

SAT 11.03		The orchestrated approach: multidisciplinary excellence in (early) psoriasis management? Chairs: Knut Schäkel (Heidelberg, Germany) Enikö Sonkoly (Uppsala, Sweden)
SAT 11.03.01	13:00	Setting the stage in psoriasis Knut Schäkel (Heidelberg, Germany)
SAT 11.03.02	13:10	The overture: early intervention in dermatology Enikö Sonkoly (Uppsala, Sweden)
SAT 11.03.03	13:22	The harmony of joints: early intervention in rheumatology Richard Smith (Salisbury, United Kingdom)
SAT 11.03.04	13:34	The rhythm of the gut: early intervention in gastroenterology Alexander Moschen (Linz, Austria)
SAT 11.03.05	13:46	Conducting the orchestra: skin, joint, and gut Knut Schäkel (Heidelberg, Germany) Enikö Sonkoly (Uppsala, Sweden) Richard Smith (Salisbury, United Kingdom) Alexander Moschen (Linz, Austria)
SAT 11.03.06	13:58	The grand finale: closing remarks Knut Schäkel (Heidelberg, Germany)

* No access to INDUSTRY badges



Satellite Symposia

Thursday, 1 October 2026

SAT 5.04

Room: Hall F2

Access: Session open to all

Time: 17:45 – 19:15 CEST

Medscape
EDUCATION GLOBAL

Medscape Education Global

Supported by an independent educational
grant from SkinCeuticals

SAT 5.04		Restoring the Face of Metabolic Health: Innovations in Treating GLP-1-Induced Aesthetic Changes Chair: Jared Jagdeo (New York, United States)
SAT 5.04.01	17:45	Understanding “GLP-1 Face” – A New Aesthetic Paradigm Jared Jagdeo (New York, United States) Sonya J. Abdulla (Toronto, Canada) Peter Bjerring (Aalborg, Denmark) Taryn Winter Brill (New York, United States)
SAT 5.04.02	18:05	Targeted Dermal Recovery – Scientific Breakthroughs Jared Jagdeo (New York, United States) Sonya J. Abdulla (Toronto, Canada) Peter Bjerring (Aalborg, Denmark) Taryn Winter Brill (New York, United States)
SAT 5.04.03	18:25	Multimodal Treatment Planning – Protocols for Real-World Practice Jared Jagdeo (New York, United States) Sonya J. Abdulla (Toronto, Canada) Peter Bjerring (Aalborg, Denmark) Taryn Winter Brill (New York, United States)
SAT 5.04.04	18:45	Patient Communication and Ethical Considerations Jared Jagdeo (New York, United States) Sonya J. Abdulla (Toronto, Canada) Peter Bjerring (Aalborg, Denmark) Taryn Winter Brill (New York, United States)
SAT 5.04.05	19:05	Q&A Jared Jagdeo (New York, United States) Sonya J. Abdulla (Toronto, Canada) Peter Bjerring (Aalborg, Denmark) Taryn Winter Brill (New York, United States)

Satellite Symposia

Thursday, 1 October 2026

SAT 6.04

Room: Hall E1

Access: HCP and Non Member (INDUSTRY)

Time: 17:45 – 19:15 CEST



Cheplapharm

SAT 6.04		Isotretinoin in the age of the algorithm: from misinformation to confident use Chair: Vincenzo Bettoli (Ferrara, Italy)
SAT 6.04.01	17:45	Welcome and introduction Vincenzo Bettoli (Ferrara, Italy)
SAT 6.04.02	17:55	From Tiktok to treatment: how social media is driving the acne conversation Marco Rocha (São Paulo, Brazil)
SAT 6.04.03	18:15	Why timing matters: early intervention, remission and scar prevention Vincenzo Bettoli (Ferrara, Italy)
SAT 6.04.04	18:35	Getting isotretinoin right: restoring confidence in practical use Tess McPherson (Oxford, United Kingdom)
SAT 6.04.05	18:55	Q&A Vincenzo Bettoli (Ferrara, Italy) Marco Rocha (São Paulo, Brazil) Tess McPherson (Oxford, United Kingdom)

Satellite Symposia

Thursday, 1 October 2026

SAT 10.04

Room: Hall M

Access: HCP only *

Time: 17:45 – 19:15 CEST



SAT 10.04		The psoriasis composition: Early treatment and sustained control from skin to joint disease Chair: Diamant Thaçi (Lübeck, Germany)
SAT 10.04.01	17:45	Prelude: Redefining treatment goals in psoriasis Diamant Thaçi (Lübeck, Germany)
SAT 10.04.02	18:00	Movement: Achieving early inflammation control beyond skin clearance Maria-Angeliki Gkini (London, UK) Richard Langley (Halifax, Canada)
SAT 10.04.03	18:30	Crescendo: Intercepting progression across skin, high-impact areas, and joints April Armstrong (Los Angeles, United States) Joseph Merola (Dallas, United States)
SAT 10.04.04	19:00	Coda: Key reflections and clinical takeaways Diamant Thaçi (Lübeck, Germany)
SAT 10.04.05	19:10	Q&A Diamant Thaçi (Lübeck, Germany) Maria-Angeliki Gkini (London, UK) Richard Langley (Halifax, Canada) April Armstrong (Los Angeles, United States) Joseph Merola (Dallas, United States)

* No access to INDUSTRY badges

This symposium is organized and funded by Novartis and is intended for an audience of non-UK HCPs within the context of the EADV Congress 2026 in Vienna, Austria.

FA-11694814 June 2026



Satellite Symposia

Thursday, 1 October 2026

SAT 11.04

Room: Hall N

Access: HCP and Non Member (INDUSTRY)

Time: 17:45 – 18:45 CEST



SAT 11.04		Redefining treatment success in psoriasis: moving beyond PASI to sustained disease control Chair: Ulrich Mrowietz (Kiel, Germany)
SAT 11.04.01	17:45	Redefining treatment success through patient-centered care Ulrich Mrowietz (Kiel, Germany)
SAT 11.04.02	17:55	How to integrate patient perspectives into treatment decisions: insights from the POSITIVE study Matthias Augustin (Hamburg, Germany)
SAT 11.04.03	18:10	Where it matters most: managing psoriasis in high-impact areas and ageing populations Anna López-Ferrer (Barcelona, Spain)
SAT 11.04.04	18:25	Achieving sustained disease control in complex patients through tailored treatment with tildrakizumab Paolo Gisondi (Verona, Italy)
SAT 11.04.05	18:40	Closing: Q&A Ulrich Mrowietz (Kiel, Germany) Matthias Augustin (Hamburg, Germany) Anna López-Ferrer (Barcelona, Spain) Paolo Gisondi (Verona, Italy)

Is face & neck atopic dermatitis a concept to consider? Can we obtain long-term disease control in psoriasis?

Join the Almirall scientific programme to discuss and find out.

AD HUB

Looking into the face of AD: tackling clinical cases in moderate-to-severe atopic dermatitis with face and neck involvement including lebrikizumab ▼

Thursday, 1 October | From 9:15 to 10:00 CEST | HUB 2.07
HUB 2, -2.41 / -2.42, Level -2



Chair, Prof. Christian Vestergaard
Assoc. Prof. Marie Jachiet

Symposium on psoriasis

Redefining treatment success in psoriasis: moving beyond PASI to sustained disease control

Thursday, 1 October | From 17:45 to 18:45 CEST | SAT 11.04
Hall N, Level 1



Chair, Prof. Ulrich Mrowietz
Prof. Matthias Augustin
Prof. Anna López-Ferrer
Prof. Paolo Gisondi

Symposium on atopic dermatitis

The many faces of AD – spotlight on visible burden, deep response, and simplicity in everyday care with lebrikizumab ▼

Friday, 2 October | From 13:00 to 14:00 CEST | SAT 5.06
Hall F2, Level 0



Chair, Dr. Christine Bangert
Prof. Diamant Thaçi
Dr. Constanza Riquelme



Access EBGLYSS® full SmPC by scanning the QR code



UK and Irish healthcare professionals

Access UK and Irish prescribing information and adverse event reporting by scanning the QR code

AD, atopic dermatitis. PASI, Psoriasis Area Severity Index.

▼ EBGLYSS® is approved by EMA and authorised for commercialisation in a number of key markets including Germany, Spain and the United Kingdom.

These sessions are organized and funded by Almirall S.A. Almirall product will be discussed. Audience is HCP only.



Learn more about our initiatives and download the calendar invite at
www.almiralldermatologycongress.com

Satellite Symposia

Friday, 2 October 2026

	Morning symposia 07:30 - 08:15		Lunch symposia 13:00 - 14:00	
Hall D			SAT 1.06	L'Oréal Dermatological Beauty Acne, Seborrheic & Atopic Dermatitis Clinical Insights
Hall B			SAT 2.06	LEO Pharma Chronic Hand Eczema: patients, cases, treatment advances
Hall C			SAT 3.06	Galderma Advancing AD & PN outcomes: Targeting for IL-31
Hall F1			SAT 4.06	UCB Palmoplantar pustulosis
Hall F2			SAT 5.06	Almirall, S.A. Atopic dermatitis: The Many Faces of AD – Spotlight on visible Burden, Deep Response, and Simplicity in Everyday Care with Lebrikizumab
Hall E1	SAT 6.05	AbbVie Advancing clinical practice in alopecia areata (AA)	SAT 6.06	Bioderma Atopic dermatitis
Hall E2			SAT 7.06	AbbVie Minimal disease activity in atopic dermatitis
Hall G				
Hall K			SAT 8.04	Sanofi Exploring unmet needs across the patient journey
Hall M	SAT 10.05	MSD Decoding Immune-Fibrotic Crosstalk in Hidradenitis Suppurativa: From Mechanisms to Clinical Decision- Making	SAT 10.06	Incyte Moderate atopic dermatitis management
Hall N			SAT 11.06	Sanofi / Regeneron Chronic Spontaneous Urticaria

Access restricted to healthcare professionals (HCPs) and INDUSTRY badges.
 Access restricted to Healthcare Professionals (HCPs) only. No access to INDUSTRY badges.
 Session open to all



Satellite Symposia

Friday, 2 October 2026

SAT 6.05

Room: Hall E1

Access: HCP and Non Member (INDUSTRY)

Time: 07:30 – 08:15 CEST

abbvie

AbbVie

SAT 6.05		Redefining the dermatology horizon: Transforming care in alopecia areata Chair: Sergio Vañó Galván (Madrid, Spain)
SAT 6.05.01	07:30	Patient voices: Living with alopecia areata Pre-recorded video
SAT 6.05.02	07:32	Welcome and introduction Sergio Vañó Galván (Madrid, Spain)
SAT 6.05.03	07:34	Beyond hair loss: The everyday reality of alopecia areata Leona Yip (Brisbane, Australia) Sergio Vañó Galván (Madrid, Spain)
SAT 6.05.04	07:49	Transforming alopecia areata care: An evolving landscape Vimal Prajapati (Calgary, Canada) Sergio Vañó Galván (Madrid, Spain)
SAT 6.05.05	08:04	Treatment strategies to optimise outcomes in alopecia areata Sergio Vañó Galván (Madrid, Spain) Leona Yip (Brisbane, Australia) Vimal Prajapati (Calgary, Canada)
SAT 6.05.06	08:12	Summary and close Sergio Vañó Galván (Madrid, Spain)

Satellite Symposia

Friday, 2 October 2026

SAT 10.05

Room: Hall M

Access: Session open to all

Time: 07:30 – 08:15 CEST



SAT 10.05		Decoding Immune Fibrotic Cross Talk in Hidradenitis Suppurativa: From Mechanisms to Decisions, What Practicing Dermatologist Should Know Chair: Errol Prens (Rotterdam, Netherlands)
SAT 10.05.01	07:30	Welcome and Objectives Errol Prens (Rotterdam, Netherlands)
SAT 10.05.02	07:33	Decoding HS: Unmasking the Hidden Disease Burden Christos Zouboulis (Neuruppin, Germany)
SAT 10.05.03	07:40	Decoding Fibroblast Subpopulations and Effector Roles in Skin Inflammation and Scarring in HS James Krueger (New York, United States)
SAT 10.05.04	07:50	Decoding TL1A biology in HS: Role of TL1A in HS pathogenesis Errol Prens (Rotterdam, Netherlands)
SAT 10.05.05	08:00	Clinical Implications Errol Prens (Rotterdam, Netherlands)
SAT 10.05.06	08:10	Q&A Errol Prens (Rotterdam, Netherlands) Christos Zouboulis (Neuruppin, Germany) James Krueger (New York, United States)

Satellite Symposia

Friday, 2 October 2026

SAT 1.06

Room: Hall D

Access: HCP and Non Member (INDUSTRY)

Time: 13:00 – 14:00 CEST

L'ORÉAL
Dermatological Beauty

L'Oréal Dermatological Beauty

SAT 1.06		From Microbiome to Skin Barrier Dysfunction: New Clinical Insights Across Acne, Seborrheic Dermatitis & Atopic Dermatitis Chair: Enzo Berardesca (Miami, United States)
SAT 1.06.01	13:00	From Microbiome to Skin Barrier Dysfunction: New Clinical Insights Across Acne, Seborrheic Dermatitis & Atopic Dermatitis (Introduction) Enzo Berardesca (Miami, United States)
SAT 1.06.02	13:03	The Microbiome Revolution in Acne: Going Beyond Bacteria- The Hidden Fungal Players Reshaping Our Understanding of Acne Cécile Clavaud (Paris, France)
SAT 1.06.03	13:10	From Face to Trunk: Closing the Treatment Gap with Real-World Evidence Jerry Tan (Windsor, Canada)
SAT 1.06.04	13:18	The Microbiome at the core of Scalp Seborrheic Dermatitis, New Clinical Evidence for Anti-Relapse and Maintenance Strategies Michela Starace (Bologna, Italy)
SAT 1.06.05	13:33	Between the Flare: Addressing the Persistent Skin Barrier Dysfunction & Subclinical Inflammation in Atopic Dermatitis Enzo Berardesca (Miami, United States)
SAT 1.06.06	13:48	Conclusion and Q&A Enzo Berardesca (Miami, United States)

Satellite Symposia

Friday, 2 October 2026

SAT 2.06

Room: Hall B

Access: HCP and Non Member (INDUSTRY)

Time: 13:00 – 14:00 CEST



LEO Pharma

SAT 2.06		The hands we see, the lives they impact: Advancing care in Chronic Hand Eczema Chair: Ahmad Jalili (Buochs, Switzerland)
SAT 2.06.01	13:00	Look beyond: The life behind the hands¹⁻³ Ahmad Jalili (Buochs, Switzerland)
SAT 2.06.02	13:05	Running on autopilot: Buried under habit³⁻⁶ Alexander Zink (Munich, Germany)
SAT 2.06.03	13:15	Breaking the cycle^{3,7} April Armstrong (Los Angeles, United States)
SAT 2.06.04	13:35	Real patients. Real lessons. Real lives Felicity Ferguson (London, United Kingdom)
SAT 2.06.05	13:50	Go beyond: Make a conscious choice^{3,8} Ahmad Jalili (Buochs, Switzerland) April Armstrong (Los Angeles, United States) Alexander Zink (Munich, Germany) Felicity Ferguson (London, United Kingdom)

References

1. Grant L, et al. *Adv Ther* 2020;37:692–706.
2. Bewley A, et al. *J Dermatolog Treat* 2026;37:2644023.
3. Silverberg JI, et al. *Am J Clin Dermatol* 2026;27:227–245.
4. Molin S, et al. *Acta Derm Venereol* 2026;15:106:adv44493.
5. Egeberg A, et al. *JAAD Int* 2023;14:77–83.
6. Thyssen JP, et al. *Contact Dermatitis* 2022;86:357–378.
7. Maskey AR, et al. *Front Allergy* 2025;6:1547923.
8. Bauer A, et al. *J Dtsch Dermatol Ges* 2023;21:1054–1074.

This is a promotional symposium intended for healthcare professionals only. This symposium is organized and funded by LEO Pharma © July 2026 LEO Pharma A/S. LEO Pharma A/S, Industriparken 55, DK-2750, Ballerup, Denmark, CVR no.: 56 75 95 14. All LEO Pharma Trademarks mentioned belong to LEO Pharma A/S. All rights reserved. MAT-95739 | June 2026

Satellite Symposia

Friday, 2 October 2026

SAT 3.06

Room: Hall C

Access: HCP and Non Member (INDUSTRY)

Time: 13:00 – 14:00 CEST

GALDERMA

EST. 1981

Galderma

SAT 3.06		Advancing treatment outcomes in AD and PN: Targeting the IL-31 neuroimmune pathways Chair: Sarina Elmariah (San Francisco, United States)
SAT 3.06.01	13:00	Welcome and opening Sarina Elmariah (San Francisco, United States)
SAT 3.06.02	13:05	PART 1 – Understanding the burden of disease, including itch, in AD and PN Stephan Weidinger (Kiel, Germany)
SAT 3.06.03	13:25	PART 2 – The role of neuroimmune cytokines in AD and PN beyond itch Sarina Elmariah (San Francisco, United States)
SAT 3.06.04	13:35	PART 3 – Improving treatment outcomes and quality of life with advanced therapies Andrew Pink (Surrey, United Kingdom)
SAT 3.06.05	13:50	Summary and Q&A Sarina Elmariah (San Francisco, United States) Andrew Pink (Surrey, United Kingdom) Stephan Weidinger (Kiel, Germany)

Satellite Symposia

Friday, 2 October 2026

SAT 4.06

Room: Hall F1

Access: HCP and Non Member (INDUSTRY)

Time: 13:00 – 14:00 CEST



UCB

SAT 4.06		Let's Talk About Pustules: Palmoplantar Pustulosis! Recognising a Distinct and Burdensome Disease Chair: Ulrich Mrowietz (Kiel, Germany)
SAT 4.06.01	13:00	Welcome and Introduction Ulrich Mrowietz (Kiel, Germany)
SAT 4.06.02	13:05	Understanding Palmoplantar Pustulosis: A Distinct and Under-Recognised Inflammatory Disease Ulrich Mrowietz (Kiel, Germany)
SAT 4.06.03	13:20	Diagnosing PPP: Practical Tips and Common Pitfalls Tina Bhutani (San Francisco, United States)
SAT 4.06.04	13:35	Managing PPP: The Need for Effective Treatments Richard Warren (Manchester, United Kingdom)
SAT 4.06.05	13:50	Q&A Ulrich Mrowietz (Kiel, Germany) Tina Bhutani (San Francisco, United States) Richard Warren (Manchester, United Kingdom)

Satellite Symposia

Friday, 2 October 2026

SAT 5.06

Room: Hall F2

Access: HCP and Non Member (INDUSTRY)

Time: 13:00 – 14:00 CEST



SAT 5.06		The many faces of AD – spotlight on visible burden, deep response, and simplicity in everyday care with lebrikizumab ▼ Chair: Christine Bangert (Vienna, Austria)
SAT 5.06.01	13:00	Welcome and introduction Christine Bangert (Vienna, Austria)
SAT 5.06.02	13:05	Facing the visible burden: addressing the pathophysiology and introducing new clinical evidence for face & neck atopic dermatitis Christine Bangert (Vienna, Austria)
SAT 5.06.03	13:25	Rethinking AD control: stability and deep response across body regions in AD Diamant Thaçi (Lübeck, Germany)
SAT 5.06.04	13:45	Simplifying the journey: practical considerations in modern AD management Constanza Riquelme (Barcelona, Spain)
SAT 5.06.05	13:55	Q&A and closing Christine Bangert (Vienna, Austria) Diamant Thaçi (Lübeck, Germany) Constanza Riquelme (Barcelona, Spain)

▼ EBGLYSS® is approved by EMA and authorised for commercialisation in a number of key markets including Germany, Spain and the United Kingdom. Access EBGLYSS® full SmPC clicking [here](#)



Satellite Symposia

Friday, 2 October 2026

SAT 6.06

Room: Hall E1

Access: Session open to all

Time: 13:00 – 14:00 CEST

BIODERMA
LABORATOIRE DERMATOLOGIQUE

Bioderma

SAT 6.06		A game-changing advance in atopic dermatitis (AD) Chair: Brigitte Dréno (Nantes, France)
SAT 6.06.01	13:00	Neuroimmune interaction as a new therapeutic target of AD Kenji Kabashima (Kyoto, Japan)
SAT 6.06.02	13:15	Microbiome in AD: A missing piece in barrier dysfunction Brigitte Dréno (Nantes, France)
SAT 6.06.03	13:30	Reinforce the skin barrier: Targeting the key missing lipids Jean-François Nicolas (Lyon, France)
SAT 6.06.04	13:45	A paradigm shift improving management of AD Stéphane Fauvergne (Lyon, France)



Satellite Symposia

Friday, 2 October 2026

SAT 7.06

Room: Hall E2

Access: HCP and Non Member (INDUSTRY)

Time: 13:00 – 14:00 CEST

abbvie

Abbvie

SAT 7.06		Redefining the Dermatology Horizon: Making Visible Progress Toward Minimal Disease Activity in Atopic Dermatitis Chair: Kilian Eyerich (Freiburg, Germany)
SAT 7.06.01	13:00	Welcome & Introductions Kilian Eyerich (Freiburg, Germany)
SAT 7.06.02	13:03	Addressing the Persistent Burden of Moderate-to-Severe AD: Exploring New Frontiers in Advanced Systemic Therapy Kilian Eyerich (Freiburg, Germany)
SAT 7.06.03	13:10	Beyond Moderate Treatment Targets in AD: The Value of Achieving Minimal Disease Activity Kilian Eyerich (Freiburg, Germany) Pedro Mendes-Bastos (Lisbon, Portugal)
SAT 7.06.04	13:25	It's Visible: Addressing the Persistent Burden of Head and Neck AD Pedro Mendes-Bastos (Lisbon, Portugal) Marni Wiseman (Winnipeg, Canada)
SAT 7.06.05	13:40	Balancing the Benefit-Risk of Advanced Systemic Therapies: An Expanding Evidence Base Marni Wiseman (Winnipeg, Canada)
SAT 7.06.06	13:50	Future Directions & Panel Discussion Kilian Eyerich (Freiburg, Germany) Marni Wiseman (Winnipeg, Canada) Pedro Mendes-Bastos (Lisbon, Portugal)

Satellite Symposia

Friday, 2 October 2026

SAT 8.04

Room: Hall K

Access: Session open to all

Time: 13:00 – 14:00 CEST

sanofi

Sanofi

SAT 8.04		From Storm to Shore: Charting the Course in HS Care Chairs: Hessel van der Zee (Rotterdam, Netherlands) Martina Porter (Boston, United States) Jeremy Hinshton (Phoenix, United States)
SAT 8.04.01	13:00	Lost in the Fog: The Hidden Burden of HS Before Recognition Hessel van der Zee (Rotterdam, Netherlands)
SAT 8.04.02	13:10	Reaching the Lighthouse: Understanding the Diagnostic Journey and Pathophysiology of HS Hessel van der Zee (Rotterdam, Netherlands)
SAT 8.04.03	13:20	Rough Waters: Striving for Durable Disease Control Martina Porter (Boston, United States)
SAT 8.04.04	13:30	Whirlpool Decisions: Shared Decision Making with Patients Hessel van der Zee (Rotterdam, Netherlands)
SAT 8.04.05	13:40	New Horizons: The Future of HS Treatment Landscape Martina Porter (Boston, United States)
SAT 8.04.06	13:55	Q&A, Key Takeaways, and Closing Remarks Hessel van der Zee (Rotterdam, Netherlands)



Satellite Symposia

Friday, 2 October 2026

SAT 10.06

Room: Hall M

Access: HCPs only *

Time: 13:00 – 14:00 CEST



Incyte

SAT 10.06		Next episode: The dawn of a new era in moderate atopic dermatitis management Chair: Matthias Augustin (Hamburg, Germany)
SAT 10.06.01	13:00	Overcoming current barriers to optimal care in moderate AD Matthias Augustin (Hamburg, Germany)
SAT 10.06.02	13:20	New approach in targeting JAK-STAT signaling in moderate AD, a multi-pathway disease Andreas Pinter (Frankfurt, Germany)
SAT 10.06.03	13:35	Translating ruxolitinib cream data for moderate AD into clinical practice Vimal Prajapati (Calgary, Canada)
SAT 10.06.04	13:50	Q&A discussion Matthias Augustin (Hamburg, Germany) Andreas Pinter (Frankfurt, Germany) Vimal Prajapati (Calgary, Canada)

* No access to INDUSTRY badges



EADV 2026

FRIDAY, 2 OCTOBER 2026

13:00–14:00 CEST

HALL M, AUSTRIA CENTER

VIENNA, AUSTRIA

This session is restricted to
Healthcare Professionals only

NEXT EPISODE: THE DAWN OF A NEW ERA IN MODERATE AD MANAGEMENT EXPERT SYMPOSIUM

SESSIONS

- Chair and Q&A moderator | **Prof. Matthias Augustin (Germany)**
- Overcoming current barriers to optimal care in moderate AD | **Prof. Matthias Augustin (Germany)**
- New approach in targeting JAK-STAT signaling in moderate AD, a multi-pathway disease | **Prof. Andreas Pinter (Germany)**
- Translating ruxolitinib cream data for moderate AD into clinical practice | **Dr Vimal H. Prajapati (Canada)**
- Discussion | **All**

SPONSORED BY
INCYTE BIOSCIENCES
INTERNATIONAL SÀRL



Satellite Symposia

Friday, 2 October 2026

SAT 11.06

Room: Hall N

Access: HCP and Non Member (INDUSTRY)

Time: 13:00 – 14:00 CEST

sanofi | REGENERON®

Sanofi / Regeneron

SAT 11.06		Stepping Up: Expert Perspectives on CSU From Diagnosis to Disease Control Chair: Martin Metz (Berlin, Germany)
SAT 11.06.01	13:00	Welcome and Introductions Martin Metz (Berlin, Germany)
SAT 11.06.02	13:05	Beyond the Itch and Hives: The Full Impact of CSU Moshe Ben-Shoshan (Montréal, Canada)
SAT 11.06.03	13:20	Simplifying the CSU Patient Journey: Diagnosis, Treatment, and Control Michelle Tarbox (Lubbock, United States)
SAT 11.06.04	13:35	Treatment Escalation in Adult and Pediatric Patients: How, When, and Why? Martin Metz (Berlin, Germany)
SAT 11.06.05	13:55	Audience Q&A Martin Metz (Berlin, Germany) Moshe Ben-Shoshan (Montréal, Canada) Michelle Tarbox (Lubbock, United States)

Industry Expert Hubs

Wednesday, 30 September 2026

	Hub 1 -2.93-94	Hub 2 -2.41-42
11:15 - 12:00	<u>HUB 1.03</u>	
	CHA Meditech Co. Ltd., Advances in Regenerative Aesthetics with Nidosome Technology	
14:15 - 15:00	<u>HUB 1.04</u>	<u>HUB 2.04</u>
	Shanghai Shangmei Cosmetics Co., Ltd CCM Satellite Symposium	Eucerin Epigenetics / Ageing process reversal/ skin longevity / Epigenetic clocks / Innovation in dermocosmetics
15:15 - 16:00	<u>HUB 1.05</u>	<u>HUB 2.05</u>
	Sanofi / Regeneron Prurigo Nodularis	Kenvue New Hydration Evidence in Compromised Skin
16:15 - 17:00	<u>HUB 1.06</u>	<u>HUB 2.06</u>
	Wuxi Zhiyan Biotechnology Co., Ltd. New Frontiers in Dermatological Care: Clinical Advances in Scalp Health, Photoprotection and Acne Treatment Management	Eucerin Hyperpigmentation, pigmentation disorders, photodamage, photoprotection, psychodermatology, and stigmatization

Access restricted to healthcare
professionals (HCPs) and
INDUSTRY badges.

Access restricted to Healthcare
Professionals (HCPs) only.
No access to INDUSTRY badges.

Session open to all



Industry Expert Hubs

Wednesday, 30 September 2026

HUB 1.03

Room: Hub 1 -2.93-94

Access: Session open to all

Time: 11:15 – 12:00 CEST

CHAMEDITECH
|주| 차메디텍

CHA Meditech Co., Ltd

HUB 1.03		Advances in Regenerative Aesthetics with Nidosome Technology
HUB 1.03.01	11:15	Nidosome-Based Treatment for Hair Loss and Scalp Conditions Eneida Kote (Istanbul, Turkiye)



Industry Expert Hubs

Wednesday, 30 September 2026

HUB 1.04

Room: Hub 1 -2.93-94

Access: Session open to all

Time: 14:15 – 15:00 CEST

CCM
上美股份

Shanghai Shangmei
Cosmetics Co., Ltd

HUB 1.04		CCM Satellite Symposium Chair: Bin Yang (Guangzhou, China)
HUB 1.04.01	14:15	Cyclic Peptides for Multi-Dimensional Skin Rejuvenation: From Mechanistic Insights to Clinical Validation Ye Zhong (Shanghai, China)
HUB 1.04.02	14:23	Artemisia Naphtha Oil AN+ and Skin Barrier Homeostasis: From Barrier Homeostasis Modulation to Dermatologist-Assessed Clinical Evidence in Sensitive Skin Li Ye (Guangzhou, China)
HUB 1.04.03	14:38	Advancing Sensitive Skin Care in Asia: Dermatology Expert Perspectives, Real-World Needs, and Evidence-Based Skin Homeostasis Solutions Bin Yang (Guangzhou, China) Jian Sun (Shanghai, China) Li Ye (Guangzhou, China) Yang Song (Shanghai, China) Ye Zhong (Shanghai, China)



Industry Expert Hubs

Wednesday, 30 September 2026

HUB 2.04

Room: Hub 2 -2.41-42

Access: Session open to all

Time: 14:15 – 15:00 CEST



Eucerin

HUB 2.04		Epigenetics as the Foundation for Skin Longevity: From Breakthrough Science to Aesthetic Practice Chair: Hassan Galadari (Dubai, United Arab Emirates)
HUB 2.04.01	14:15	Longevity Science and Epigenetics Ted Lain (Austin, United States)
HUB 2.04.02	14:23	Translating and Integrating Epigenetics into Aesthetic Clinical Practice Lilia Guadanhim (Sao Paulo, Brazil)
HUB 2.04.03	14:38	From Breakthrough Science to innovative dermocosmetics Paula Pitta (Hamburg, Germany)
HUB 2.04.04	14:46	Real-World Evidence and Clinical Experience Hassan Galadari (Dubai, United Arab Emirates)



Industry Expert Hubs

Wednesday, 30 September 2026

HUB 1.05

Room: Hub 1 -2.93-94

Access: HCPs only *

Time: 15:15 – 16:00 CEST

sanofi | REGENERON®

Sanofi / Regeneron

HUB 1.05		Transforming Prurigo Nodularis Care in 2026: New Real-World Evidence for Comprehensive Care and Treatment Optimization Chair: Pedro Bastos (Lisbon, Portugal)
HUB 1.05.01	15:15	Welcome and Introductions Pedro Bastos (Lisbon, Portugal)
HUB 1.05.02	15:20	The Ripple Effect: Uncovering the Hidden Burden and Comorbidities of Prurigo Nodularis Sarina Elmariah (San Francisco, United States)
HUB 1.05.03	15:30	From Data to Decision: Unleashing Real-World Evidence for Smart Treatment Selection Pedro Bastos (Lisbon, Portugal)
HUB 1.05.04	15:40	The Big Picture: Real-World Strategies for Durable Relief and Transforming Patient Lives Pedro Bastos (Lisbon, Portugal) Sarina Elmariah (San Francisco, United States)
HUB 1.05.05	15:55	Audience Q&A and Closing Pedro Bastos (Lisbon, Portugal) Sarina Elmariah (San Francisco, United States)

* No access to INDUSTRY badges



Industry Expert Hubs

Wednesday, 30 September 2026

HUB 2.05

Room: Hub 2 -2.41-42

Access: Session open to all

Time: 15:15 – 16:00 CEST



Kenvue

HUB 2.05		Raising the Bar-rier: New Hydration Evidence in Compromised Skin Chair: Asha Patel Shah (Summit, United States)
HUB 2.05.01	15:15	Welcome Asha Patel Shah (Summit, United States)
HUB 2.05.02	15:20	Cleansing Without Compromise: BarrierCare® Cleansing Technology's Role in Supporting Barrier Integrity Ted Lain (Austin, United States) Asha Patel Shah (Summit, United States)
HUB 2.05.03	15:28	Barrier Boosting: Optimising Patient Outcomes with Improved Barrier Strength & Hydration Ted Lain (Austin, United States) Asha Patel Shah (Summit, United States)
HUB 2.05.04	15:36	Moisturising to Maximise: Enhancing Dermatologic Treatment & Post-Procedure Outcomes Through Adjunctive Hydrating Skincare Ted Lain (Austin, United States) Asha Patel Shah (Summit, United States)
HUB 2.05.05	15:55	Q&A Asha Patel Shah (Summit, United States) Ted Lain (Austin, United States)



Neutrogena®

Raising the Bar-rier: New Hydration Evidence in Compromised Skin

featuring Hydro Boost
your perfect hydration partner for all treatment plans

Industry Expert Hub

Wednesday, 30th September

Time : 15.15 - 16.00h

Location : Hub 2.05, Level - 2

Meet Our Speakers

CHAIR



Dr. Asha Patel Shah
MD, MBA, FAAD
(United States)



Dr. Patricia Farris
MD, FAAD
(United States)



Dr Ted Lain
MD, MBA, FAAD
(United States)



ULTRA SHEER®
THE SCIENCE OF SUN PROTECTION

Introducing Ultra Sheer® Invisible Fluid Hydration, SPF 50

Advanced 3-in-1 Protection with Premium Aesthetics

Powered by Helioplex SL™ Technology Next Generation Filters*
Antioxidants Vit C, Vit E, Niacinamide
Intense, 24-Hour Hydration



Come visit us at Booth X313 in the Exhibition Hall to learn about our latest innovations

Regaine®

Neutrogena®

Aveeno®

NEOSTRATA®

Exhibition area is open to Healthcare Professionals only

Industry Expert Hubs

Wednesday, 30 September 2026

HUB 1.06

Room: Hub 1 -2.93-94

Access: HCP and Non Member (INDUSTRY)

Time: 16:15 – 17:00 CEST

ZIYOND 知原
ZRVIVE 质润

Wuxi Zhiyan
Biotechnology Co., Ltd.

HUB 1.06		New Frontiers in Dermatological Care: Clinical Advances in Scalp Health. Photoprotection and Acne Treatment Management Chairs: Peter Wolf (Graz, Austria) Jianzhong Zhang (Beijing, China)
HUB 1.06.01	16:15	Future Directions in Photoprotection and Seborrheic Scalp Health Peter Wolf (Graz, Austria)
HUB 1.06.02	16:30	Patented Innovation in Dandruff Care: Selenium Sulfide and Supramolecular Technology Beilei Cai (Wuxi, China)
HUB 1.06.03	16:45	Sarecycline in Chinese Patients with Acne Vulgaris: Results from the Phase III Clinical Study Jianzhong Zhang (Beijing, China)



Industry Expert Hubs

Wednesday, 30 September 2026

HUB 2.06

Room: Hub 2 -2.41-42

Access: Session open to all

Time: 16:15 – 17:00 CEST



Eucerin

HUB 2.06		Hyperpigmentation Management for Patient-Centric Outcomes: Safe & Effective Treatment Approaches for all Types of Hyperpigmentation Chair: Seemal R. Desai (Dallas, United States)
HUB 2.06.01	16:15	From Global Consensus to Clinical Practice: A Unified Vision for Hyperpigmentation Management Thierry Passeron (Paris, France)
HUB 2.06.02	16:30	Mastering Hyperpigmentation: From Visible Light-Induced Pathways to Long-Term Control Seemal R. Desai (Dallas, United States)
HUB 2.06.03	16:45	From Clinical Signs to Patient Experience: The Human Impact of Hyperpigmentation Ncoza Dlova (Durban, South Africa)



Industry Expert Hubs

Thursday, 1 October 2026

	Hub 1 -2.93-94	Hub 2 -2.41-42
09:15 - 10:00	<u>HUB 1.07</u>	<u>HUB 2.07</u>
	AVENE Wound healing / Scars / Hyperpigmentation / Dark phototype / Dermocosmetic	Almirall Atopic Dermatitis: Looking Into the Face of AD: Tackling Clinical Cases in Moderate-to- Severe Atopic Dermatitis with Face and Neck Involvement including lebrikizumab
10:15 - 11:00	<u>HUB 1.08</u>	<u>HUB 2.08</u>
	DEXERYL Role of emollients in psoriasis	AbbVie Non-segmental vitiligo (NSV) current and future care
11:15 - 12:00	<u>HUB 1.09</u>	<u>HUB 2.09</u>
	Galderma Targeting cellular senescence to counter skin aging and dermatoporosis: A science- driven innovation for skin longevity	ISDIN Resetting Skin Equilibrium: The Evolution of Photoprotection
14:15 - 15:00	<u>HUB 1.10</u>	<u>HUB 2.10</u>
	Laboratoire Dermatologique ACM Rethinking Hyperpigmentation Management: An Exclusive Tranexamic Acid Formulation	Istituto Ganassini Sensitive & Acne prone Skin
15:15 - 16:00	<u>HUB 1.11</u>	<u>HUB 2.11</u>
	Ducray Beyond the face: the hidden burden of truncal acne	LEO Pharma A/S Pyoderma gangrenosum
16:15 - 17:00	<u>HUB 1.12</u>	<u>HUB 2.12</u>
	Cantabria Labs Antiaging / Senescence / Longevity / Senotherapeutics	Vichy Laboratoires Longevity / Integrative health / collagen science / skin procedures / scalp procedures / collagen supplements

Access restricted to healthcare professionals (HCPs) and INDUSTRY badges.
 Access restricted to Healthcare Professionals (HCPs). No access to INDUSTRY badges.
 Session open to all



Industry Expert Hubs

Thursday, 1 October 2026

HUB 1.07

Room: Hub 1 -2.93-94

Access: Session open to all

Time: 09:15 – 10:00 CEST

EAU THERMALE
Avène
LABORATOIRE DERMATOLOGIQUE

AVENE

HUB 1.07		Healing should leave no marks Chair: Ncoza Dlova (Durban, South Africa)
HUB 1.07.01	09:15	Dark skin types: the blind spot in wound healing? Ncoza Dlova (Durban, South Africa)
HUB 1.07.02	09:28	Dermatologist's desk: when the skin no longer follows the rules Edward Lain (Austin, United States)
HUB 1.07.03	09:41	When screens shape scars: celebrity, pop culture, and the skin of color experience Nicolas Kluger (Helsinki, Finland)



Industry Expert Hubs

Thursday, 1 October 2026

HUB 2.07

Room: Hub 2 -2.41-42

Access: HCP and Non Member (INDUSTRY)

Time: 09:15 – 10:00 CEST



HUB 2.07		Looking into the face of AD: tackling clinical cases in moderate-to-severe atopic dermatitis with face and neck involvement including lebrikizumab ▼ Chair: Christian Vestergaard (Aarhus, Denmark)
HUB 2.07.01	09:15	Welcome and introduction Christian Vestergaard (Aarhus, Denmark)
HUB 2.07.02	09:20	The wish for urgent relief, and stable response in the visible areas and beyond - Including discussions of cases on face & neck AD Christian Vestergaard (Aarhus, Denmark) Marie Jachiet (Paris, France)
HUB 2.07.03	09:35	Maintaining long-term sustained response in AD including challenging areas - Including discussions of cases on face & neck AD Christian Vestergaard (Aarhus, Denmark) Marie Jachiet (Paris, France)
HUB 2.07.04	09:55	Q&A and closing Christian Vestergaard (Aarhus, Denmark) Marie Jachiet (Paris, France)

▼ EBGLYSS® is approved by EMA and authorised for commercialisation in a number of key markets including Germany, Spain and the United Kingdom. Access EBGLYSS® full SmPC clicking [here](#)

Industry Expert Hubs

Thursday, 1 October 2026

HUB 1.08

Room: Hub 1 -2.93-94

Access: Session open to all

Time: 10:15 – 11:00 CEST

DEXERYL[®]
DERMATOLOGICAL EXPERTISE

DEXERYL

HUB 1.08		Psoriasis as a whole skin disease: inflammation, barrier dysfunction and the role of emollients in symptom relief Chair: Jean-François Nicolas (Lyon, France) Paolo Gisondi (Verona, Italy)
HUB 1.08.01	10:15	Why using emollients in psoriasis? Jean-François Nicolas (Lyon, France)
HUB 1.08.02	10:30	When and how using emollients in psoriasis? Paolo Gisondi (Verona, Italy)



Industry Expert Hubs

Thursday, 1 October 2026

HUB 2.08

Room: Hub 2 -2.41-42

Access: HCP and Non Member (INDUSTRY)

Time: 10:15 – 11:00 CEST

abbvie

AbbVie

HUB 2.08		Redefining the dermatology horizon: Navigating the evolving vitiligo landscape Chair: Seemal Desai (Dallas, United States)
HUB 2.08.01	10:15	Welcome and introduction Seemal Desai (Dallas, United States)
HUB 2.08.02	10:17	Understanding the real-world impact and unmet needs in vitiligo today Seemal Desai (Dallas, United States)
HUB 2.08.03	10:25	Evolving the standards of care in non-segmental vitiligo Marni Wiseman (Winnipeg, Canada)
HUB 2.08.04	10:39	The current and emerging landscape in non-segmental vitiligo care Thierry Passeron (Nice, France) Marni Wiseman (Winnipeg, Canada)
HUB 2.08.05	10:57	Summary and close Seemal Desai (Dallas, United States)



Industry Expert Hubs

Thursday, 1 October 2026

HUB 1.09

Room: Hub 1 -2.93-94

Access: HCPs only *

Time: 11:15 – 12:00 CEST

GALDERMA

EST. 1981

Galderma

HUB 1.09		Targeting cellular senescence to counter skin aging and dermatoporosis: A science-driven innovation for skin longevity Chair: Adam Friedman (Washington, DC, United States)
HUB 1.09.01	11:15	Welcome and introduction Adam Friedman (Washington DC, United States)
HUB 1.09.02	11:18	Cetaphil® SKIN ACTIVATOR Hydrating & Firming Cream with SeneDefy™ Technology Adam Friedman (Washington DC, United States) Glynis Ablon (Manhattan Beach, United States)
HUB 1.09.03	11:40	The longevity framework: A new vision for skin health Alan Widgerow (Carlsbad, United States)
HUB 1.09.04	11:50	Panel discussion Adam Friedman (Washington DC, United States) Glynis Ablon (Manhattan Beach, United States) Alan Widgerow (Carlsbad, United States)

* No access to INDUSTRY badges



Industry Expert Hubs

Thursday, 1 October 2026

HUB 2.09

Room: Hub 2 -2.41-42

Access: Session open to all

Time: 11:15 – 12:00 CEST



ISDIN

HUB 2.09		Protect & Reset: Moving Beyond Damage Repair in Photoprotection Toward Restoring Skin's Biological Resilience Chair: Jaime Piquero (Barcelona, Spain)
HUB 2.09.01	11:15	The skin exposome: Understanding the drivers of modern skin aging Jaime Piquero (Barcelona, Spain)
HUB 2.09.02	11:25	After Sun Exposure: What Happens Next? Josep Malvehy (Barcelona, Spain)
HUB 2.09.03	11:40	Double Helix Reset Technology: Restoring Skin Equilibrium Anthony Brown (Barcelona, Spain)
Hub 2.09.04	11:55	Q&A Jaime Piquero (Barcelona, Spain)



Industry Expert Hubs

Thursday, 1 October 2026

HUB 1.10

Room: Hub 1 -2.93-94

Access: Session open to all

Time: 14:15 – 15:00 CEST

ACM
LABORATOIRE
DERMATOLOGIQUE

Laboratoire
Dermatologique ACM

HUB 1.10		Rethinking Hyperpigmentation Management: An Exclusive Tranexamic Acid Formulation Chair: Thierry Passeron (Nice, France)
HUB 1.10.01	14:15	Welcome and introduction Thierry Passeron (Nice, France)
HUB 1.10.02	14:20	Beyond Pigment: The Role of Vascular Components in Hyperpigmentation Thierry Passeron (Nice, France)
HUB 1.10.03	14:30	The Power of Topical Tranexamic Acid : New Formulation Better Penetration Maria Vitale (Madrid, Spain)
HUB 1.10.04	14:45	Matching the Gold Standard: Clinical Evaluation Versus Hydroquinone 4% Thierry Passeron (Nice, France)
HUB 1.10.05	14:55	Q&A Thierry Passeron (Nice, France) Maria Vitale (Madrid, Spain)

Industry Expert Hubs

Thursday, 1 October 2026

HUB 2.10

Room: Hub 2 -2.41-42

Access: HCP and Non Member (INDUSTRY)

Time: 14:15 – 15:00 CEST



sensilis | Sensitive Skin Lab

Istituto Ganassini

HUB 2.10		Beyond the Barrier: New Biological Insights and Treatment options in Sensitive & Fragile Skin Chairs: Vincenzo Bettoli (Bologna, Italy) Alicia Barreiro Capurro (Barcelona, Spain) Juan García Gavín (Santiago de Compostela, Spain) Claudia Menicanti (Milano, Italy)
HUB 2.10.01	14:15	Sensitive Skin: What Lies Beneath? – An Anatomical Pathology Perspective Claudia Menicanti (Milano, Italy)
HUB 2.10.02	14:25	The Sebaceous Gland as an Immunometabolic Hub: From Sebum Biology to Cutaneous Inflammation Alicia Barreiro Capurro (Barcelona, Spain)
HUB 2.10.03	14:35	Linking Sebum Biology to Clinical Phenotypes: Sebogenic Convergence in Acne, Rosacea, and Sensitive Skin Juan García Gavín (Santiago de Compostela, Spain)
HUB 2.10.04	14:45	Fragile Skin: the case of the Modern Correct and Personalized use of Isotretinoin Vincenzo Bettoli (Bologna, Italy)

Industry Expert Hubs

Thursday, 1 October 2026

HUB 1.11

Room: Hub 1 -2.93-94

Access: Session open to all

Time: 15:15 – 16:00 CEST



Ducray

HUB 1.11		Beyond the face: the hidden burden of truncal acne Chair: Valérie Mengeaud (Lavaur, France)
HUB 1.11.01	15:15	More severe, less seen: the psychosocial paradox of truncal acne Marco Rocha (Sao Paulo, Brazil)
HUB 1.11.02	15:30	Truncal acne: from physiopathology to optimized patient management Brigitte Dréno (Nantes, France)
HUB 1.11.03	15:50	Clinical evidence and truncal acne of a new body spray containing myrtacine and celastrol Marco Rocha (Sao Paulo, Brazil)



Industry Expert Hubs


Thursday, 1 October 2026

HUB 2.11

Room: Hub 2 -2.41-42

Access: HCP and Non Member (INDUSTRY)

Time: 15:15 – 16:00 CEST



LEO Pharma A/S

HUB 2.11		Going Beyond Ulcers: A Deeper Look at PG Chair: Alex Ortega Loayza (Portland, United States)
HUB 2.11.01	15:15	Welcome and Introductions Alex Ortega Loayza (Portland, United States)
HUB 2.11.02	15:20	Recognizing PG Early: What is Your First Step Toward Diagnosis? Arash Mostaghimi (Boston, United States)
HUB 2.11.03	15:29	Managing PG Today: What Does Real-World Care Look Like? Jacek Szepietowski (Wrocław, Poland)
HUB 2.11.04	15:37	Future of PG Treatment: What Are We Missing in Current PG Management? Arash Mostaghimi (Boston, United States)
HUB 2.11.05	15:46	PG Ulcers Have Healed: What Do We Do Next? Jacek Szepietowski (Wrocław, Poland)
HUB 2.11.06	15:54	Q&A Alex Ortega Loayza (Portland, United States) Jacek Szepietowski (Wrocław, Poland) Arash Mostaghimi (Boston, United States)

Industry Expert Hubs

Thursday, 1 October 2026

HUB 1.12

Room: Hub 1 -2.93-94

Access: Session open to all

Time: 16:15 – 17:00 CEST



Cantabria Labs

HUB 1.12		Reverting Skin Senescence: A New Senotherapeutic Approach Chair: Maria Vitale (Madrid, Spain)
HUB 1.12.01	16:15	Understanding Skin Senescence Hassan Galadari (Al Ain, United Arab Emirates)
HUB 1.12.02	16:35	A New Antiaging Technology: Molecular Mechanisms Irene Caceres Estevez (Madrid, Spain)
HUB 1.12.03	16:45	A New Antiaging Technology: Clinical Results Maria Vitale (Madrid, Spain)



Discover the **SCIENCE THAT CARES...**

Reverting Skin Senescence: A New Senotherapeutic Approach

SENEBLOCK
EXCLUSIVE TECHNOLOGY

Thursday, October 1st, 2026
16:15 – 17:00 | ACV, Level -2

INDUSTRY EXPERTS HUB 1.12



**A New Antiaging Technology:
Molecular Mechanisms**

Irene Cáceres

MSc

Scientific Research Specialist
Cantabria Labs



**Understanding
Skin Senescence**

Hassan Galadari

MD FAAD

Associate Professor of Dermatology
United Arab Emirates University



**A New Antiaging
Technology: Clinical Results**

María Vitale

MD

Medical Manager Dermatology
Cantabria Labs

Visit our **BOOTH X505 (LEVEL 0, HALL X5)** and learn
more about our latest innovations and science

Access to the exhibition area is restricted to Healthcare Professionals only

Industry Expert Hubs

Thursday, 1 October 2026

HUB 2.12

Room: Hub 2 -2.41-42

Access: HCP and Non Member (INDUSTRY)

Time: 16:15 – 17:00 CEST



HUB 2.12		Integrative approach in the era of longevity Chair: Pascale Mora (Clichy, France)
HUB 2.12.01	16:15	Integrative approach in the era of longevity Pascale Mora (Clichy, France)
HUB 2.12.02	16:20	The Collagen Atlas: Mapping the Dermal Matrix Across Ages and Skin Types Frederic Flament (Clichy, France)
HUB 2.12.03	16:29	Adjunctive strategies for Skin Procedures: From Mechanism to Clinical Study Results Mukta Sachdev (Bengaluru, India)
HUB 2.12.04	16:38	Maximizing Scalp Procedure Outcomes With Dermocosmetics Natalia Kovytkina (Paris, France)
HUB 2.12.05	16:47	Beyond Topicals: Clinical Evidence for Collagen Supplements Thiviyani Maruthappu (London, United Kingdom)
HUB 2.12.06	16:56	Q&A Pascale Mora (Clichy, France) Frederic Flament (Clichy, France) Mukta Sachdev (Bengaluru, India) Natalia Kovytkina (Paris, France) Thiviyani Maruthappu (London, United Kingdom)



Industry Expert Hubs

Friday, 2 October 2026

	Hub 1 -2.93-94	Hub 2 -2.41-42
09:15 - 10:00	<u>HUB 1.13</u>	<u>HUB 2.13</u>
	ADERMA Face eczema / Burden / Dermocosmetic supportive care	Eli Lilly and Company Psoriasis, Psoriasis and comorbidities, Psoriasis and obesity
10:15 - 11:00	<u>HUB 1.14</u>	<u>HUB 2.14</u>
	Ducray Hair / Scalp / Side effects / GLP1 agonist / Survey results	Medscape Education Global Chronic Hand Eczema and Atopic Dermatitis with Hand Involvement
11:15 - 12:00	<u>HUB 1.15</u>	<u>HUB 2.15</u>
	Blueprint Medicines, a Sanofi company Mastocytosis	SkinCeuticals Maximizing outcomes by integrating skincare with procedures.
14:15 - 15:00	<u>HUB 1.16</u>	<u>HUB 2.16</u>
	AVENE Acne / Acne Marks / Skin Of Color / Invisible Burden	LEO Pharma A/S Generalized Pustular Psoriasis
15:15 - 16:00	<u>HUB 1.17</u>	<u>HUB 2.17</u>
	Eucerin Xerosis / Skin Barrier Restoration / Atopic Dermatitis / Pruritus	Novartis Pharma AG Chronic Inducible Urticaria
16:15 - 17:00	<u>HUB 1.18</u>	
	Procter and Gamble Scalp sensitivity / Seborrheic Dermatitis / Teenager / Firmness / Peptides	

Access restricted to healthcare professionals (HCPs) and INDUSTRY badges.

Access restricted to Healthcare Professionals (HCPs). No access to INDUSTRY badges.

Session open to all



Industry Expert Hubs

Friday, 2 October 2026

HUB 1.13

Room: Hub 1 -2.93-94

Access: Session open to all

Time: 09:15 – 10:00 CEST

LABORATOIRE
A-DERMA
ADERMA

HUB 1.13		Facial eczema: when a visible disease becomes a daily burden Chair: Valérie Mengeaud (Lavaur, France)
HUB 1.13.01	09:15	Facial eczema: the invisible impact of highly visible disease Bruno Halioua (Paris, France)
HUB 1.13.02	09:30	Facial eczema: a therapeutic challenge and the role of supportive dermocosmetic care Christian Vestergaard (Skoedstrup, Denmark)



Industry Expert Hubs

Friday, 2 October 2026

HUB 2.13

Room: Hub 2 -2.41-42

Access: HCP and Non Member (INDUSTRY)

Time: 09:15 – 10:00 CEST



Eli Lilly and Company

HUB 2.13		Meet the Expert: Practical Considerations for Addressing Weight Management in Patients With Psoriasis and Overweight/Obesity Chair: Lluís Puig Sanz (Barcelona, Spain)
HUB 2.13.01	09:15	Setting the Scene: The Impact of Overweight/Obesity on Psoriasis Outcomes Lluís Puig Sanz (Barcelona, Spain)
HUB 2.13.02	09:20	Rethinking Psoriasis: Bridging New Evidence and Practical Weight Management Strategies Sascha Gerdes (Kiel, Germany)
HUB 2.13.03	09:30	What Dermatologists Should Know About GIP and GLP-1 Receptor Agonists Andrew Blauvelt (Baltimore, United States)
HUB 2.13.04	09:40	Expert Roundtable: Learnings for Practical Patient Management Lluís Puig Sanz (Barcelona, Spain) Sascha Gerdes (Kiel, Germany) Andrew Blauvelt (Baltimore, United States)
HUB 2.13.05	09:55	Closing Remarks Lluís Puig Sanz (Barcelona, Spain)



Industry Expert Hubs

Friday, 2 October 2026

HUB 1.14

Room: Hub 1 -2.93-94

Access: Session open to all

Time: 10:15 – 11:00 CEST



Ducray

HUB 1.14		What dermatologists need to know about the GLP1 revolution Chair: Valérie Mengeaud (Lavaur, France)
HUB 1.14.01	10:15	GLP1: what we know today? Bianca Maria Piraccini (Bologna, Italy)
HUB 1.14.02	10:25	Sharing the results of a survey from 4 countries on GLP1 dermatologic impacts: a multinational case-control study Bruno Halioua (Paris, France)
HUB 1.14.03	10:40	Patients on GLP1 therapy: understanding dermatological risks and managing outcomes Bianca Maria Piraccini (Bologna, Italy)



Industry Expert Hubs

Friday, 2 October 2026

HUB 2.14

Room: Hub 2 -2.41-42

Access: HCP and Non Member (INDUSTRY)

Time: 10:15 – 11:00 CEST

Medscape
EDUCATION GLOBAL

Medscape Education Global

Supported by an independent educational
grant from LEO Pharma A/S

HUB 2.14		Evolving Strategies in Managing Chronic Hand Eczema and Atopic Dermatitis with Hand Involvement
HUB 2.14.01	10:15	Explore How CHE Differs Clinically From AD With Hand Involvement Jason Williams (Manchester, United Kingdom) April Armstrong (Los Angeles, California, United States)
HUB 2.14.02	10:21	Case 1: Patient With Moderate CHE Failing on TCS Jason Williams (Manchester, United Kingdom)
HUB 2.14.03	10:35	Case 2: Patient With Moderate to Severe AD on the Body With Hand Involvement April Armstrong (Los Angeles, California, United States)
HUB 2.14.04	10:49	Q&A Jason Williams (Manchester, United Kingdom) April Armstrong (Los Angeles, California, United States)
HUB 2.14.05	10:59	Summary and Conclusions Jason Williams (Manchester, United Kingdom)

Industry Expert Hubs

Friday, 2 October 2026

HUB 1.15

Room: Hub 1 -2.93-94

Access: HCP and Non Member (INDUSTRY)

Time: 11:15 – 12:00 CEST



Blueprint Medicines,
a Sanofi company

HUB 1.15		A New Era in Mastocytosis: The Dermatologist's Role in Identifying Systemic Disease and Enabling Treatment Chair: Sabine Altrichter (Linz, Austria)
HUB 1.15.01	11:15	Welcome and Introductions Sabine Altrichter (Linz, Austria)
HUB 1.15.02	11:20	From Cutaneous Manifestations to Systemic Disease: Evolving Understanding in Mastocytosis Sabine Altrichter (Linz, Austria)
HUB 1.15.03	11:35	Targeting the Disease Driver in Systemic Mastocytosis: Current Treatment Options and Emerging Therapies Polina Pyatilova (Berlin, Germany)
HUB 1.15.04	11:50	Q&A Sabine Altrichter (Linz, Austria) Polina Pyatilova (Berlin, Germany)



Industry Expert Hubs

Friday, 2 October 2026

HUB 2.15

Room: Hub 2 -2.41-42

Access: Session open to all

Time: 11:15 – 12:00 CEST

 SKINCEUTICALS

SkinCeuticals

HUB 2.15		Advanced Skincare Innovations Tailored for All Aesthetic Patients
HUB 2.15.01	11:15	Global Expert Consensus: Enhancement of Aesthetic Procedures with Skincare Hema Sundaram (Rockville, United States)
HUB 2.15.02	11:28	Maximizing Outcomes: SkinCeuticals Phyto Corrective PDRN for Pre/Post-Treatments and Acne Care Chengfeng Zhang (Shanghai, China)
HUB 2.15.03	11:41	SkinCeuticals P-TIOX: Integrated Skincare Outcomes and Male Patient Insights Geeta Yadav (Toronto, Canada)
HUB 2.15.04	11:54	Q&A Hema Sundaram (Rockville, United States) Chengfeng Zhang (Shanghai, China) Geeta Yadav (Toronto, Canada)



Industry Expert Hubs

Friday, 2 October 2026

HUB 1.16

Room: Hub 1 -2.93-94

Access: Session open to all

Time: 14:15 – 15:00 CEST



AVENE

HUB 1.16		Acne beyond the lesions: a broader view of patient burden Chair: Mukta Sachdev (Bangalore, India)
HUB 1.16.01	14:15	Recognizing diversity: clinical nuances in skin of color Mukta Sachdev (Bangalore, India)
HUB 1.16.02	14:28	Reducing lasting damage: addressing scars and hyperpigmentation Cheri Frey (Suitland, United States)
HUB 1.16.03	14:41	Redefining skin health beyond the surface with psychodermatology Diala Haykal (Paris, France)



Industry Expert Hubs


Friday, 2 October 2026

HUB 2.16

Room: Hub 2 -2.41-42

Access: HCP and Non Member (INDUSTRY)

Time: 14:15 – 15:00 CEST



LEO Pharma A/S

HUB 2.16		Looking Beyond the Skin: Practical Insights and Clinical Experience in GPP Care Chair: Constanze Jonak (Vienna, Austria)
HUB 2.16.01	14:15	Welcome and Introduction: Why GPP Requires a Different Clinical Perspective Constanze Jonak (Vienna, Austria)
HUB 2.16.02	14:20	Beyond Flare Resolution: Understanding the Full Burden of GPP Stan Tolkachjov (Lewisville, United States)
HUB 2.16.03	14:28	Recognizing GPP Beyond the Pustules: Understanding a Distinct Disease María Asunción Ballester-Martínez (Madrid, Spain)
HUB 2.16.04	14:36	The Evolving Management of GPP: Translating Insights Into Clinical Practice Stan Tolkachjov (Lewisville, United States)
HUB 2.16.05	14:44	Challenges in Clinical Practice: Scenario-Based Discussion and Q&A Constanze Jonak (Vienna, Austria) Stan Tolkachjov (Lewisville, United States) María Asunción Ballester-Martínez (Madrid, Spain)

Industry Expert Hubs

Friday, 2 October 2026

HUB 1.17

Room: Hub 1 -2.93-94

Access: Session open to all

Time: 15:15 – 16:00 CEST



Eucerin

HUB 1.17		Mastering Barrier Dysfunctions: From Physical Repair to Emotional Healing Chair: Bader Zimmo (Jeddah, Saudi Arabia)
HUB 1.17.01	15:15	Skin Barrier Impairment in Dry, Itchy and Inflamed Skin Bader Zimmo (Jeddah, Saudi Arabia)
HUB 1.17.02	15:20	Writing History: Evidence-Based Topical Formulations for Dry Skin Management Katharina Weitzel (Hamburg, Germany)
HUB 1.17.03	15:27	Atopic Dermatitis: Breaking the Itch Cycle – Making the Unconscious Conscious with Habit-Reversal Treatment Uwe Gielert (Gießen, Germany)
HUB 1.17.04	15:45	Xerosis: Are You Itching to See the Barrier Repaired? Clinical and Ultrastructural Evidence Bader Zimmo (Jeddah, Saudi Arabia)



Industry Expert Hubs

Friday, 2 October 2026

HUB 2.17

Room: Hub 2 -2.41-42

Access: HCP only *

Time: 15:15 – 16:00 CEST



HUB 2.17		Predictable or not: Cracking the CIndU code Chair: Sabine Altrichter (Linz, Austria)
HUB 2.17.01	15:15	Beyond the trigger: The hidden biology of CIndU Sabine Altrichter (Linz, Austria)
HUB 2.17.02	15:35	From avoidance to control: Rethinking CIndU treatment Heike Rockmann (Utrecht, The Netherlands)
HUB 2.17.03	15:55	Rapid-fire expert exchange & takeaways Sabine Altrichter (Linz, Austria) Heike Rockmann (Utrecht, The Netherlands)

* No access to INDUSTRY badges



Industry Expert Hubs

Friday, 2 October 2026

HUB 1.18

Room: Hub 1 -2.93-94

Access: Session open to all

Time: 16:15 – 17:00 CEST



Procter and Gamble

HUB 1.18		Advanced Care for Scalp and Skin: Sensitivity, Dandruff, Firmness Chair: Cedric Callens (Geneva, Switzerland)
HUB 1.18.01	16:15	Scalp sensitivity in an increasingly allergy-prone world: implications for scalp care and dandruff management Torsten Zuberbier (Berlin, Germany)
HUB 1.18.02	16:30	Why Teen dandruff matters: clinical insights into scalp care routines and confidence Birgit Blessmann-Gurk (Hamburg, Germany)
HUB 1.18.03	16:45	Making skin firmness visible: turning complex skin science into clear patient benefits Etienne Camel (Lyon, France)